According to the partners, DSP-0038 combines serotonin 5-HT2A receptor antagonism and 5-HT1A receptor agonism – two well established targets for antipsychotic drugs – in a single small molecule.

Axovant turned its attention to another neuroscience drug – 5-HT2A receptor inverse agonist nelotanserin, licensed from Arena Pharma – but that failed a phase 2 study in REM sleep behaviour ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...